Robert Glassman, M.D., is Executive Vice President, Search & Evaluation at Enavate Sciences. Dr. Glassman is instrumental in the origination and evaluation of potential investments and supports the strategic growth, governance, and other long-term planning initiatives for portfolio companies.

Rob is an industry veteran with nearly 30 years of health care leadership and investment experience. Most recently, he was a venture partner in public equity at OrbiMed Advisors, returning to the firm after serving as a private equity partner. Previously, he worked as a senior investment banking professional for over seventeen years across Credit Suisse, Merrill Lynch, Bank of America, most recently serving as Vice Chairman of the Global Health Care Investment Banking division at Credit Suisse. Earlier in his career, Dr. Glassman oversaw health care investments at Merrill Lynch Global Private Equity and was a consultant within McKinsey & Company’s Pharmaceutical and Medical Products practice. Dr. Glassman was a board-certified hematologist-oncologist and remains on the faculty of Weill Cornell as a Clinical Assistant Professor of Medicine. He also spent several years as a basic science investigator at Rockefeller University in the laboratory of Hidesaburo Hanafusa, where he received Howard Hughes Medical Institute and American Cancer Society awards. Dr. Glassman currently serves as a board member for Pharvaris, Umoja, Portage Biotech and Jubilant.

Dr. Glassman earned his A.B. from Harvard College and an M.D. from Harvard Medical School.

Return to Team